New hope for liver cancer: experimental drug HH-009 enters human trials

NCT ID NCT07547553

Recruiting now Disease control Sponsor: Huahui Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called HH-009 in people with advanced liver cancer that has worsened after other treatments. About 30 participants will receive one of two doses to see if it can slow or stop cancer growth. The goal is to find out if the drug is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HH-009 injection
What this could lead to: If this trial succeeds, HH-009 could offer a new treatment option for people with advanced liver cancer who have not responded to other therapies.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply to everyone. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Affiliated Tumor Hospital of Guangxi Medical University
NOT_YET_RECRUITING

Nanning, Guangxi, China
Anhui Provincial Hospital
NOT_YET_RECRUITING

Hefei, Anhui, China
Capital Medical University Affiliated Beijing Ditan Hospital
RECRUITING

Beijing, Beijing Municipality, China
Guangxi Zhuang Autonomous Region People's Hospital
NOT_YET_RECRUITING

Nanning, Guangxi, China
Harbin Medical University Affiliated Cancer Hospital
NOT_YET_RECRUITING

Harbin, Heilongjiang, China
Henan Provincial Cancer Hospital
NOT_YET_RECRUITING

Zhengzhou, Henan, China
Jiangxi Cancer Hospital
NOT_YET_RECRUITING

Nanchang, Jiangxi, China
Jilin University First Hospital
NOT_YET_RECRUITING

Changchun, Jilin, China
Liaoning Cancer Hospital
NOT_YET_RECRUITING

Shenyang, Liaoning, China
Mengchao Hepatobiliary Hospital of Fujian Medical University
NOT_YET_RECRUITING

Fuzhou, Fujian, China
NanFang Hospital of Southern Medical University
NOT_YET_RECRUITING

Guangzhou, Guangdong, China
Nanjing Tianyinshan Hospital
RECRUITING

Nanjing, Jiangsu, China
Shanghai Gaobo Tumor Hospital
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, China
Shao Yi Fu Hospital, Affiliated to the School of Medicine of Zhejiang University
NOT_YET_RECRUITING

Hangzhou, Zhejiang, China
The Fifth Medical Center of the PLA General Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, China
The First Affiliated Hospital of Anhui Medical University
NOT_YET_RECRUITING

Hefei, Anhui, China
The First Affiliated Hospital of Bengbu Medical University
NOT_YET_RECRUITING

Bengbu, Anhui, China
The First Affiliated Hospital of Henan Medical University
RECRUITING

Zhengzhou, Henan, China
Tianjin Medical University Cancer Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, China
Wells Prince Hospital of The Chinese University of Hong Kong
NOT_YET_RECRUITING

Hong Kong, Hong Kong, China
Zhongshan Hospital Affiliated to Fudan University
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, China